Use of liraglutide in the medicinal therapeutic approach of non-alcoholic steatohepatitis (NASH)
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/18921 |
Resumo: | To evaluate the effects of liraglutide administration on NASH. Consists of a systematic review of the literature in the main virtual libraries: US National Library of Medicine National Institutes of Health (PubMed), Biblioteca Virtual de Saúde (BVS), Scientific Electronic Library Online (SCIELO) and Latin American and Caribbean Literature in Health Sciences (LILACS) in the last five years, admitting articles from clinical trials. Liraglutide is an analogue of the glacagon 1-like peptide hormone (GLP-1) that acts in suppressing appetite and de novo lipogenesis (DNL), decreasing glucagon release, increasing insulin release and sensitization, among others. For these reasons, its fronts to combat NASH range from the reduction and control of the lipid profile, to the repair of hepatocytes. Currently, with the obesogenic environment found in society, drug therapy has become a great ally of the medical community, as well as in facilitating goals for the patient. The use of liraglutide in NASH proved to be effective in slowing and resolving it, with therapies ranging from 26 to 48 weeks and doses ranging from 0,9 mg to 3,0 mg. |
id |
UNIFEI_a3d0d21329eaf4c06be5704f9745426b |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/18921 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Use of liraglutide in the medicinal therapeutic approach of non-alcoholic steatohepatitis (NASH)Uso de liraglutida em el enfoque terapéutico medicinal de la esteatohepatitis no alcohólica (EHNA)Utilização da liraglutida na abordagem terapêutica medicamentosa da esteato- hepatite não alcoólica (EHNA)Hepatopatia Gordurosa não AlcoólicaTratamento FarmacológicoLiraglutida.Non-alcoholic Fatty Liver DiseaseDrug TherapyLiraglutide.Enfermedad del hígado graso no alcohólicoQuimioterapiaLiraglutida.To evaluate the effects of liraglutide administration on NASH. Consists of a systematic review of the literature in the main virtual libraries: US National Library of Medicine National Institutes of Health (PubMed), Biblioteca Virtual de Saúde (BVS), Scientific Electronic Library Online (SCIELO) and Latin American and Caribbean Literature in Health Sciences (LILACS) in the last five years, admitting articles from clinical trials. Liraglutide is an analogue of the glacagon 1-like peptide hormone (GLP-1) that acts in suppressing appetite and de novo lipogenesis (DNL), decreasing glucagon release, increasing insulin release and sensitization, among others. For these reasons, its fronts to combat NASH range from the reduction and control of the lipid profile, to the repair of hepatocytes. Currently, with the obesogenic environment found in society, drug therapy has become a great ally of the medical community, as well as in facilitating goals for the patient. The use of liraglutide in NASH proved to be effective in slowing and resolving it, with therapies ranging from 26 to 48 weeks and doses ranging from 0,9 mg to 3,0 mg.Evaluar los efectos de la administración de liraglutida sobre NASH. Consiste en una revision sistemática de la literature en las principals bibliotecas virtuales: US National Library of Medicine National Institutes of Health (PubMed), Biblioteca Virtual de Saúde (BVS), Scientific Electronic Library Online (SCIELO) y Latin American and Caribbean Literature in Science (LILACS) em los últimos cinco años, admitiendo artículos de ensayos clínicos. La liraglutida es un análogo de la hormona peptídica similar al glacagón 1 (GLP-1) que actúa para suprimir el apetito y lalipogénesis de novo (DNL), diminuir la liberación de glucagón, aumentar la liberación de insulina y la sensibilización, entre otros. Por estos motivos, sus frentes para combatirla EHNA van desde la reducción y control del perfil lipídico, hasta la reparación de hepatocitos. Actualmente, conel entorno obesogénico que se vive em la sociedad, lafarmacoterapia se convierteenungran aliado de la comunidad médica, así como en facilitar metas para el paciente. El uso de liraglutidaen EHNA demostró ser eficaz en su desaceleración y resolución, con terapias que van de 26 a 48 semanas y dosis de 0,9 mg a 3,0 mg.Avaliar os efeitos da administração de liraglutida na EHNA. Consiste em uma revisão sistemática da literatura nas principais bibliotecas virtuais: US National Library of Medicine National Institutes of Health (PubMed), Biblioteca Virtual de Saúde (BVS), Scientific Electronic Library Online (SCIELO) e Literatura Latino-americana e do Caribe em ciências da Saúde (LILACS) nos últimos cinco anos, admitindo os artigos provenientes de ensaios clínicos. A liraglutida é um análogo do hormônio peptídeo semelhante a glacagon 1 (GLP-1) que atua na supressão do apetite e da lipogênese de novo (DNL), diminuição da liberação do glucagon, aumento da liberação e sensibilização insulínica entre outros. Por esses motivos, suas frentes de combate a EHNA vão desde a diminuição e controle do perfil lipídico, até a reparação dos hepatócitos. Atualmente, com o ambiente obesogênico encontrado na sociedade, a terapia medicamentosa torna-se uma grande aliada da comunidade médica, assim como na facilitação das metas para o paciente. O uso da liraglutida na EHNA mostrou-se eficaz no seu desaceleramento e resolutividade, com terapias variando de 26 a 48 semanas e doses de 0,9 mg a 3,0 mg.Research, Society and Development2021-08-14info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1892110.33448/rsd-v10i10.18921Research, Society and Development; Vol. 10 No. 10; e389101018921Research, Society and Development; Vol. 10 Núm. 10; e389101018921Research, Society and Development; v. 10 n. 10; e3891010189212525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/18921/16947Copyright (c) 2021 Anna Camilla Ferreira Lopes Valério Pinto; Osman Batista de Medeiros Filho; Milena Nunes Alves de Sousa; Hugo David Maia Nascimento Linshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessPinto, Anna Camilla Ferreira Lopes Valério Medeiros Filho, Osman Batista deSousa, Milena Nunes Alves deLins, Hugo David Maia Nascimento 2021-10-02T21:49:16Zoai:ojs.pkp.sfu.ca:article/18921Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:38:56.291090Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Use of liraglutide in the medicinal therapeutic approach of non-alcoholic steatohepatitis (NASH) Uso de liraglutida em el enfoque terapéutico medicinal de la esteatohepatitis no alcohólica (EHNA) Utilização da liraglutida na abordagem terapêutica medicamentosa da esteato- hepatite não alcoólica (EHNA) |
title |
Use of liraglutide in the medicinal therapeutic approach of non-alcoholic steatohepatitis (NASH) |
spellingShingle |
Use of liraglutide in the medicinal therapeutic approach of non-alcoholic steatohepatitis (NASH) Pinto, Anna Camilla Ferreira Lopes Valério Hepatopatia Gordurosa não Alcoólica Tratamento Farmacológico Liraglutida. Non-alcoholic Fatty Liver Disease Drug Therapy Liraglutide. Enfermedad del hígado graso no alcohólico Quimioterapia Liraglutida. |
title_short |
Use of liraglutide in the medicinal therapeutic approach of non-alcoholic steatohepatitis (NASH) |
title_full |
Use of liraglutide in the medicinal therapeutic approach of non-alcoholic steatohepatitis (NASH) |
title_fullStr |
Use of liraglutide in the medicinal therapeutic approach of non-alcoholic steatohepatitis (NASH) |
title_full_unstemmed |
Use of liraglutide in the medicinal therapeutic approach of non-alcoholic steatohepatitis (NASH) |
title_sort |
Use of liraglutide in the medicinal therapeutic approach of non-alcoholic steatohepatitis (NASH) |
author |
Pinto, Anna Camilla Ferreira Lopes Valério |
author_facet |
Pinto, Anna Camilla Ferreira Lopes Valério Medeiros Filho, Osman Batista de Sousa, Milena Nunes Alves de Lins, Hugo David Maia Nascimento |
author_role |
author |
author2 |
Medeiros Filho, Osman Batista de Sousa, Milena Nunes Alves de Lins, Hugo David Maia Nascimento |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Pinto, Anna Camilla Ferreira Lopes Valério Medeiros Filho, Osman Batista de Sousa, Milena Nunes Alves de Lins, Hugo David Maia Nascimento |
dc.subject.por.fl_str_mv |
Hepatopatia Gordurosa não Alcoólica Tratamento Farmacológico Liraglutida. Non-alcoholic Fatty Liver Disease Drug Therapy Liraglutide. Enfermedad del hígado graso no alcohólico Quimioterapia Liraglutida. |
topic |
Hepatopatia Gordurosa não Alcoólica Tratamento Farmacológico Liraglutida. Non-alcoholic Fatty Liver Disease Drug Therapy Liraglutide. Enfermedad del hígado graso no alcohólico Quimioterapia Liraglutida. |
description |
To evaluate the effects of liraglutide administration on NASH. Consists of a systematic review of the literature in the main virtual libraries: US National Library of Medicine National Institutes of Health (PubMed), Biblioteca Virtual de Saúde (BVS), Scientific Electronic Library Online (SCIELO) and Latin American and Caribbean Literature in Health Sciences (LILACS) in the last five years, admitting articles from clinical trials. Liraglutide is an analogue of the glacagon 1-like peptide hormone (GLP-1) that acts in suppressing appetite and de novo lipogenesis (DNL), decreasing glucagon release, increasing insulin release and sensitization, among others. For these reasons, its fronts to combat NASH range from the reduction and control of the lipid profile, to the repair of hepatocytes. Currently, with the obesogenic environment found in society, drug therapy has become a great ally of the medical community, as well as in facilitating goals for the patient. The use of liraglutide in NASH proved to be effective in slowing and resolving it, with therapies ranging from 26 to 48 weeks and doses ranging from 0,9 mg to 3,0 mg. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-08-14 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/18921 10.33448/rsd-v10i10.18921 |
url |
https://rsdjournal.org/index.php/rsd/article/view/18921 |
identifier_str_mv |
10.33448/rsd-v10i10.18921 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/18921/16947 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 10; e389101018921 Research, Society and Development; Vol. 10 Núm. 10; e389101018921 Research, Society and Development; v. 10 n. 10; e389101018921 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052753704386560 |